
Chinese General Practice ›› 2021, Vol. 24 ›› Issue (30): 3794-3798.DOI: 10.12114/j.issn.1007-9572.2021.02.002
Special Issue: 肿瘤最新文章合辑; 乳腺癌最新文章合辑
• Monographic Research • Previous Articles Next Articles
Published:2021-10-20
Online:2021-10-20
基金资助:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2021.02.002
| [1]KUSAMA S,SPRATT J S Jr,DONEGAN W L,et al. The cross rates of growth of human mammary carcinoma[J].Cancer,1972,30(2):594-599.DOI:10.1002/1097-0142(197208)30:2<594:aid-cncr2820300241>3.0.co;2-2. [2]FRIBERG S,MATTSON S.On the growth rates of human malignant tumors:implications for medical decision making[J].J Surg Oncol,1997,65(4):284-297.DOI:10.1002/(sici)1096-9098(199708)65:4<284:aid-jso11>3.0.co;2-2. [3]DUFFY S W,CHEN H H,TABAR L,et al. Estimation of mean sojourn time in breast cancer screening using a Markov chain model of both entry to and exit from the preclinical detectable phase[J].Stat Med,1995,14(14):1531-1543.DOI:10.1002/sim.4780141404. [4]LEE S,HUANG H,ZELEN M.Early detection of disease and scheduling of screening examinations[J].Stat Methods Med Res,2004,13(6):443-456.DOI:10.1191/0962280204sm377ra. [5]TAGHIPOUR S,BANJEVIC D,MILLER A B,et al. Parameter estimates for invasive breast cancer progression in the Canadian National Breast Screening Study[J].Br J Cancer,2013,108(3):542-548.DOI:10.1038/bjc.2012.596. [6]LAI M S,YEN M F,KUO H S,et al. Efficacy of breast-cancer screening for female relatives of breast-cancer-index cases:Taiwan multicentre cancer screening (TAMCAS)[J].Int J Cancer,1998,78(1):21-26.DOI:10.1002/(sici)1097-0215(19980925)78:1<21:aid-ijc5>3.0.co;2-z. [7]WU J C Y,HAKAMA M,ANTTILA A,et al. Estimation of natural history parameters of breast cancer based on non-randomized organized screening data:subsidiary analysis of effects of inter-screening interval,sensitivity,and attendance rate on reduction of advanced cancer[J].Breast Cancer Res Treat,2010,122(2):553-566.DOI:10.1007/s10549-009-0701-x. [8]TAN K H,SIMONELLA L,WEE H L,et al. Quantifying the natural history of breast cancer[J].Br J Cancer,2013,109(8):2035-2043.DOI:10.1038/bjc.2013.471. [9]WU Y Y,YEN M F,YU C P,et al. Risk assessment of multistate progression of breast tumor with state-dependent genetic and environmental covariates[J].Risk Anal,2014,34(2):367-379.DOI:10.1111/risa.12116. [10]FRYBACK D G,STOUT N K,ROSENBERG M A,et al. The Wisconsin breast cancer epidemiology simulation model[J].J Natl Cancer Inst Monogr,2006(36):37-47.DOI:10.1093/jncimonographs/lgj007. [11]ALAGOZ O,ERGUN M A,CEVIK M,et al. The University of Wisconsin Breast Cancer Epidemiology Simulation Model:an update[J].Med Decis Making,2018,38(1_suppl):99S-111.DOI:10.1177/0272989x17711927. [12]WONG I O,KUNTZ K M,COWLING B J,et al. Cost effectiveness of mammography screening for Chinese women[J].Cancer,2007,110(4):885-895.DOI:10.1002/cncr.22848. [13]KIM J K,KIM H D,JUN M J,et al. Correction to:tumor volume doubling time as a dynamic prognostic marker for patients with hepatocellular carcinoma[J].Dig Dis Sci,2017,62(11):3259.DOI:10.1007/s10620-017-4785-6. [14]KIM J K,KIM H D,JUN M J,et al. Tumor volume doubling time as a dynamic prognostic marker for patients with hepatocellular carcinoma[J].Dig Dis Sci,2017,62(10):2923-2931.DOI:10.1007/s10620-017-4708-6. [15]SABRA M M,SHERMAN E J,TUTTLE R M.Tumor volume doubling time of pulmonary metastases predicts overall survival and can guide the initiation of multikinase inhibitor therapy in patients with metastatic,follicular cell-derived thyroid carcinoma[J].Cancer,2017,123(15):2955-2964.DOI:10.1002/cncr.30690. [16]WEEDON-FEKJAER H,LINDQVIST B H,VATTEN L J,et al. Breast cancer tumor growth estimated through mammography screening data[J].Breast Cancer Res,2008,10(3):R41.DOI:10.1186/bcr2092. [17]TAGHIPOUR S,CAUDRELIER L N,MILLER A B,et al. Using simulation to model and validate invasive breast cancer progression in women in the study and control groups of the Canadian National Breast Screening StudiesⅠandⅡ[J].Med Decis Making,2017,37(2):212-223.DOI:10.1177/0272989X16660711. [18]BREKELMANS C T,WESTERS P,FABER J A,et al. Age specific sensitivity and sojourn time in a breast cancer screening programme (DOM) in The Netherlands:a comparison of different methods[J].J Epidemiol Community Health,1996,50(1):68-71.DOI:10.1136/jech.50.1.68. [19]TABAR L,FAGERBERG G,CHEN H H,et al. Efficacy of breast cancer screening by age.New results from the Swedish Two-County Trial[J].Cancer,1995,75(10):2507-2517.DOI:10.1002/1097-0142(19950515)75:10<2507:aid-cncr2820751017>3.0.co;2-h. [20]PACI E,DUFFY S W.Modelling the analysis of breast cancer screening programmes:sensitivity,lead time and predictive value in the Florence District Programme (1975—1986)[J].Int J Epidemiol,1991,20(4):852-858.DOI:10.1093/ije/20.4.852. [21]JIANG H,WALTER S D,BROWN P E,et al. Estimation of screening sensitivity and sojourn time from an organized screening program[J].Cancer Epidemiol,2016,44:178-185.DOI:10.1016/j.canep.2016.08.021. [22]TABBANE F,BAHI J,RAHAL K,et al. Inflammatory symptoms in breast cancer.Correlations with growth rate,clinicopathologic variables,and evolution[J].Cancer,1989,64(10):2081-2089.DOI:10.1002/1097-0142(19891115)64:10<2081:aid-cncr2820641019>3.0.co;2-7. [23]KUROISHI T,TOMINAGA S,MORIMOTO T,et al. Tumor growth rate and prognosis of breast cancer mainly detected by mass screening[J].Jpn J Cancer Res,1990,81(5):454-462.DOI:10.1111/j.1349-7006.1990.tb02591.x. [24]LUNDGREN B.Observations on growth rate of breast carcinomas and its possible implications for lead time[J].Cancer,1977,40(4):1722-1725.DOI:10.1002/1097-0142(197710)40:4<1722:aid-cncr2820400448>3.0.co;2-2. [25]VON FOURNIER D,WEBER E,HOEFFKEN W,et al. Growth rate of 147 mammary carcinomas[J].Cancer,1980,45(8):2198-2207.DOI:10.1002/1097-0142(19800415)45:8<2198:aid-cncr2820450832>3.0.co;2-7. [26]PEER P G,VAN DIJCK J A,HENDRIKS J H,et al. Age-dependent growth rate of primary breast cancer[J].Cancer,1993,71(11):3547-3551.DOI:10.1002/1097-0142(19930601)71:11<3547:aid-cncr2820711114>3.0.co;2-c. [27]OTTEN J D,VAN SCHOOR G,PEER P G,et al. Growth rate of invasive ductal carcinomas from a screened 50-74-year-old population[J].J Med Screen,2018,25(1):40-46.DOI:10.1177/0969141316687791. [28]马恒敏,王乐,石菊芳,等. 乳腺癌自然史模型研究系统评价:现状及构建中国人群特异性模型面临的挑战[J].中华流行病学杂志,2017,38(10):1419-1425.DOI:10.3760/cma.j.issn.0254-6450.2017.10.025. MA H L,WANG L,SHI J F,et al. A systematic review of international simulation models on the natural history of breast cancer:current understanding and challenges for Chinese-population-specific model development [J].Chin J Epidemiol,2017,38(10):1419-1425.DOI:10.3760/cma.j.issn.0254-6450.2017.10.025. [29]FRACHEBOUD J,GROENEWOUD J H,BOER R,et al. Seventy-five years is an appropriate upper age limit for population-based mammography screening[J].Int J Cancer,2006,118(8):2020-2025.DOI:10.1002/ijc.21560. [30]TILANUS-LINTHORST M M,KRIEGE M,BOETES C,et al. Hereditary breast cancer growth rates and its impact on screening policy[J].Eur J Cancer,2005,41(11):1610-1617.DOI:10.1016/j.ejca.2005.02.034. [31]TILANUS-LINTHORST M M,OBDEIJN I M,HOP W C,et al. BRCA1 mutation and young age predict fast breast cancer growth in the Dutch,United Kingdom,and Canadian magnetic resonance imaging screening trials[J].Clin Cancer Res,2007,13(24):7357-7362.DOI:10.1158/1078-0432.CCR-07-0689. [32]KRIEGE M,BREKELMANS C T,BOETES C,et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition[J].N Engl J Med,2004,351(5):427-437.DOI:10.1056/nejmoa031759. [33]BREKELMANS C T,SEYNAEVE C,BARTELS C C,et al. Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk[J].J Clin Oncol,2001,19(4):924-930.DOI:10.1200/JCO.2001.19.4.924. [34]CAUMO F,VECCHIATO F,STRABBIOLI M,et al. Interval cancers in breast cancer screening:comparison of stage and biological characteristics with screen-detected cancers or incident cancers in the absence of screening[J].Tumori,2010,96(2):198-201.DOI:10.1177/030089161009600203. [35]BREKELMANS C T,VAN GORP J M,PEETERS P H,et al. Histopathology and growth rate of interval breast carcinoma.Characterization of different subgroups[J].Cancer,1996,78(6):1220-1228.DOI:10.1002/(sici)1097-0142(19960915)78:6<1220:aid-cncr8>3.0.co;2-d. [36]NIXON R M,PHAROAH P,TABAR L,et al. Mammographic screening in women with a family history of breast cancer:some results from the Swedish two-county trial[J].Rev Epidemiol Sante Publique,2000,48(4):325-331. [37]CHEN T H,KUO H S,YEN M F,et al. Estimation of sojourn time in chronic disease screening without data on interval cases[J].Biometrics,2000,56(1):167-172.DOI:10.1111/j.0006-341x.2000.00167.x. [38]GENTILI C,SANFILIPPO O,SILVESTRINI R.Cell proliferation and its relationship to clinical features and relapse in breast cancers[J].Cancer,1981,48(4):974-979.DOI:10.1002/1097-0142(19810815)48:4<974:aid-cncr2820480420>3.0.co;2-#. [39]CHARLSON M E,FEINSTEIN A R.Rapid growth rate:a method of identifying node-negative breast cancer patients with a high risk of recurrence[J].J Chronic Dis,1983,36(12):847-853.DOI:10.1016/0021-9681(83)90005-x. [40]REBBECK T R,LEVIN A M,EISEN A,et al. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers[J].J Natl Cancer Inst,1999,91(17):1475-1479.DOI:10.1093/jnci/91.17.1475. [41]WOHLFAHRT J,ANDERSEN P K,MOURIDSEN H T,et al. Reproductive history and stage of breast cancer[J].Am J Epidemiol,1999,150(12):1325-1330.DOI:10.1093/oxfordjournals.aje.a009964. [42]RYU E B,CHANG J M,SEO M,et al. Tumour volume doubling time of molecular breast cancer subtypes assessed by serial breast ultrasound[J].Eur Radiol,2014,24(9):2227-2235.DOI:10.1007/s00330-014-3256-0. [43]LEE S H,KIM Y S,HAN W,et al. Tumor growth rate of invasive breast cancers during wait times for surgery assessed by ultrasonography[J].Medicine (Baltimore),2016,95(37):e4874.DOI:10.1097/MD.0000000000004874. [44]YOO T K,MIN J W,KIM M K,et al. In vivo tumor growth rate measured by US in preoperative period and long term disease outcome in breast cancer patients[J].PLoS One,2015,10(12):e0144144.DOI:10.1371/journal.pone.0144144. [45]TABAR L,FAGERBERG G,CHEN H H,et al. Tumour development,histology and grade of breast cancers:prognosis and progression[J].Int J Cancer,1996,66(4):413-419.DOI:10.1002/(SICI)1097-0215(19960516)66:4<413:AID-IJC1>3.0.CO;2-Z. [46]GUNSOY N B,GARCIA-CLOSAS M,MOSS S M.Modelling the overdiagnosis of breast cancer due to mammography screening in women aged 40 to 49 in the United Kingdom[J].Breast Cancer Res,2012,14(6):R152.DOI:10.1186/bcr3365. [47]MILLET I,BOUIC-PAGES E,HOA D,et al. Growth of breast cancer recurrences assessed by consecutive MRI[J].BMC Cancer,2011,11:155.DOI:10.1186/1471-2407-11-155. [48]DEMICHELI R,TERENZIANI M,BONADONNA G.Estimate of tumor growth time for breast cancer local recurrences:rapid growth after wake-up? [J].Breast Cancer Res Treat,1998,51(2):133-137.DOI:10.1023/a:1005887422022. [49]F?RNVIK D,L?NG K,ANDERSSON I,et al. Estimates of breast cancer growth rate from mammograms and its relation to tumour characteristics[J].Radiat Prot Dosimetry,2016,169(1/2/3/4):151-157.DOI:10.1093/rpd/ncv417. [50]HEUSER L,SPRATT J S,POLK H C.Growth rates of primary breast cancers[J].Cancer,1979,43(5):1888-1894.DOI:10.1002/1097-0142(197905)43:5<1888:aid-cncr2820430545>3.0.co;2-m. [51]GALANTE E,GALLUS G,GUZZON A,et al. Growth rate of primary breast cancer and prognosis:observations on a 3- to 7-year follow-up in 180 breast cancers[J].Br J Cancer,1986,54(5):833-836.DOI:10.1038/bjc.1986.247. [52]TUBIANA M,KOSCIELNY S.Natural history of human breast cancer:recent data and clinical implications[J].Breast Cancer Res Treat,1991,18(3):125-140.DOI:10.1007/BF01990028. [53]ABRAHAMSSON L,CZENE K,HALL P,et al. Breast cancer tumour growth modelling for studying the association of body size with tumour growth rate and symptomatic detection using case-control data[J].Breast Cancer Res,2015,17:116.DOI:10.1186/s13058-015-0614-z. [54]BATINA N G,TRENTHAM-DIETZ A,GANGNON R E,et al. Variation in tumor natural history contributes to racial disparities in breast cancer stage at diagnosis[J].Breast Cancer Res Treat,2013,138(2):519-528.DOI:10.1007/s10549-013-2435-z. |
| [1] | LI Jing, LIU Ziqi, QIAN Li, YAO Ruiqin. Research Progress on the Role of the Microbiota-gut-brain Axis in Epilepsy [J]. Chinese General Practice, 2026, 29(32): 4821-4826. |
| [2] | WANG Shiyi, FAN Xiaojing, SI Yafei, ZHOU Zhongliang. Advances in Key Measurement Techniques for the Intrinsic Capacity of Elderly in the Context of Healthy Aging [J]. Chinese General Practice, 2026, 29(31): 4662-4666. |
| [3] | ZHAO Jiayi, FAN Jian, YU Dehua. The Current Situation, Challenges, and Coping Strategies of Preserving Ratio Impaired Spirometry [J]. Chinese General Practice, 2026, 29(30): 4366-4371. |
| [4] | LI Xiling, ZHANG Fan, YANG Xinyue, YANG Heng. Application of Exercise Snacks in Chronic Disease Management: a Scoping Review [J]. Chinese General Practice, 2026, 29(30): 4472-4479. |
| [5] | HE Yang, YANG Rong, SHEN Can, YI Shanye, LIU Lidi, ZHAO Qian, WAN Zhi, LIAO Xiaoyang. Progress in Research on the Trajectory of Frailty and Its Influencing Factors [J]. Chinese General Practice, 2026, 29(30): 4372-4378. |
| [6] | CHEN Yujing, WANG Yan, LI Guang, DONG Benchao, YANG Peichuan, MA Jianxiong. Digital Technologies in the Management of Sarcopenia among Older Adults in Asia: a Scoping Review [J]. Chinese General Practice, 2026, 29(29): 4200-4210. |
| [7] | XIE Xiaoyun, LIU Chenxi, LIU Yushu, ZHOU Yihan. Artificial Intelligence Research Practices in Primary Healthcare Institutions in China and the Potential Issue of Data Poverty: a Scoping Review [J]. Chinese General Practice, 2026, 29(28): 4067-4077. |
| [8] | FENG Yachen, LIU Lewei, XUE Jinyue, SUN Xianlin, LIU Huanzhong. Research Progress of Wearable Technology in the Diagnosis and Treatment of Mental Disorders [J]. Chinese General Practice, 2026, 29(27): 4016-4025. |
| [9] | LIU Yahui, XU Yanan, YUAN Ling, WU Ligui, ZHOU Yujie, KANG Yubiao. A Scoping Review on Triage for Palliative Care Patients Based on Priority Decision-making [J]. Chinese General Practice, 2026, 29(24): 3538-3544. |
| [10] | WU Liyun, SUN Huajing, GU Yiqing, MEI Ziqi, JIN Shengji, ZHANG Suju, ZHU Yun, ZHANG Yao, LI Qin, LIU Xiaomiao, WANG Qing, BAI Yamei, XU Guihua. Application of Digital-intelligent Technology in Electrocardiographic Monitoring for Acute Myocardial Infarction: a Scoping Review [J]. Chinese General Practice, 2026, 29(24): 3545-3552. |
| [11] | WANG Rui, LUO Shuoming, YANG Liang, WANG Peng, ZHAO Yang, WANG Qi, ZHOU Zhiguang. Diabetes Prevalence among Older Adults in China: a Systematic Review and Meta-analysis [J]. Chinese General Practice, 2026, 29(24): 3500-3508. |
| [12] | WANG Longyu, LI Ya, MA Qian, JIA Peilin, ZHANG Hailong. Clinical Application Progress of Diffusing Capacity of the Lung for Carbon Monoxide in Chronic Obstructive Pulmonary Disease [J]. Chinese General Practice, 2026, 29(23): 3379-3384. |
| [13] | WU Ermei, SUN Dajuan, DENG Hualiang. A Review of Role of miRNA in Ulcerative Colitis and Traditional Chinese Medicine Intervention [J]. Chinese General Practice, 2026, 29(23): 3371-3378. |
| [14] | RUAN Hejing, ZHAO Wen, LI Longcan, ZHAO Jiufa, LI Dongdong. The Non-canonical Functions and Therapeutic Prospects of Parkin in Metabolic Associated Fatty Liver Disease [J]. Chinese General Practice, 2026, 29(23): 3268-3274. |
| [15] | ZHOU Mingyao, ZHANG Liuliu, HAN Renqiang, LU Ningning, WANG Dan, CHENG Fang. Barriers and Facilitators to Implementation of Screening for High-risk Populations of Breast Cancer in Communities: an Interview Study with Women, Organizers and Providers [J]. Chinese General Practice, 2026, 29(22): 3206-3213. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||